Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice
Alberto Corsini, Nicola Ferri, Marco Proietti, et al.
Drugs (2020) Vol. 80, Iss. 11, pp. 1065-1083
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice
Nicola Ferri, E. Colombo, Marco Tenconi, et al.
Pharmaceutics (2022) Vol. 14, Iss. 6, pp. 1120-1120
Open Access | Times Cited: 78
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice
Roberta Roberti, Luigi Francesco Iannone, Caterina Palleria, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 63
The Clinical Significance of Drug–Food Interactions of Direct Oral Anticoagulants
Grzegorz Grześk, Daniel Rogowicz, Łukasz Wołowiec, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8531-8531
Open Access | Times Cited: 44
Drug–Drug Interactions of FXI Inhibitors: Clinical Relevance
Nicola Ferri, E. Colombo, Alberto Corsini
Hematology Reports (2024) Vol. 16, Iss. 1, pp. 151-163
Open Access | Times Cited: 5
Pharmacokinetic drug-drug interactions of direct oral anticoagulants
Josef Suchopár, Michal Prokeš, Štěpán Suchopár
Klinická farmakologie a farmacie (2025) Vol. 39, Iss. 1, pp. 22-33
Open Access
Risk of thromboembolic events in patients Co-treated with factor xa-inhibiting direct oral anticoagulants and anti-seizure medications: insights from pharmacovigilance data
Lingqing Ding, Congqin Chen, Y. Yang, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis
Bailin Zhang, Winglam Cheng, Wulamiding Kaisaier, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21740-e21740
Open Access | Times Cited: 9
Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians
Jean Terrier, Frédéric Gaspar, Pierre Fontana, et al.
The American Journal of Medicine (2021) Vol. 134, Iss. 8, pp. 939-942
Open Access | Times Cited: 16
THE P‐GLYCOPROTEIN MULTIDRUG TRANSPORTER
Andaleeb Sajid, Sabrina Lusvarghi, Suresh V. Ambudkar
(2022), pp. 199-211
Closed Access | Times Cited: 11
Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation
Jean Terrier, Frédéric Gaspar, Monia Guidi, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 2, pp. 353-363
Open Access | Times Cited: 10
Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis
Corinne Frère, Carme Font, F. Espósito, et al.
Supportive Care in Cancer (2021) Vol. 30, Iss. 4, pp. 2919-2931
Closed Access | Times Cited: 13
Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution
Ruijuan Xu, Wenyuan Liu, Weihong Ge, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 8, pp. 1093-1106
Open Access | Times Cited: 5
Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance
Nicola Ferri, E. Colombo, Alberto Corsini
(2024)
Open Access | Times Cited: 1
Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System
Mengyao Li, Jian Xiao, Ting Yu, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 11, pp. 1453-1461
Closed Access | Times Cited: 1
Edoxaban in cardiovascular disease management: Review
Sharanyah Srinivasan, Muhammad Ajmal, Cristina Pecci, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 2, pp. 535-540
Open Access | Times Cited: 9
Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data
Levin Thomas, Sumit Birangal, Rajdeep Ray, et al.
Therapeutic Advances in Drug Safety (2021) Vol. 12
Open Access | Times Cited: 9
Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients
Valerio Langella, Roberta Bottino, Antonio Asti, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 10, pp. 1289-1294
Open Access | Times Cited: 7
Analysis of Influencing Factors of Compliance with Non-Vitamin K Antagonist Oral Anticoagulant in Patients with Nonvalvular Atrial Fibrillation and Correlation with the Severity of Ischemic Stroke
Li Zhu, Xiaodan Zhang, Jing Yang
Evidence-based Complementary and Alternative Medicine (2021) Vol. 2021, pp. 1-7
Open Access | Times Cited: 4
Use of Oral Anticoagulant Drugs in Patients with Pulmonary Hypertension
Pablo Demelo‐Rodríguez, Francisco Galeano‐Valle, Marco Proietti
Heart Failure Clinics (2022) Vol. 19, Iss. 1, pp. 97-106
Open Access | Times Cited: 3
Effectiveness and Safety of Different Oral Anticoagulants with P-glycoprotein/ CYP3A4 Inhibitors: A Network Meta-analysis
Siyu Yang, Ye Xu, Yang Zhang, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 15, pp. 1167-1177
Closed Access
Anticoagulation: Past, Present, and Future Therapies
Andrew S. Tenpas, Ladan Panahi, George Udeani, et al.
IntechOpen eBooks (2024)
Open Access
Impact of Banhabaekchulcheonmatang (Banxia Baizhu Tianma Tang) and Hwangryeonhaedoktang (Huang Lian Jie Du Tang) on Edoxaban: Herb-Drug Interaction Study in Healthy Subjects
Seok-jin Cho, Jungbin Song, Dong Wook Kang, et al.
Journal of Ethnopharmacology (2024), pp. 118997-118997
Closed Access
Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
Ryusei Mikami, Mineji Hayakawa, Shungo Imai, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 860-860
Open Access | Times Cited: 1
Novel Drug-Drug Interaction of Potential Rifabutin-Induced Edoxaban Failure: A Case Report
Cameron Lanier, Madeline Fuller, Blair Abelson Reece
Journal of Pharmacy Practice (2023) Vol. 37, Iss. 5, pp. 1199-1204
Closed Access | Times Cited: 1
Edoxaban in cardiovascular medicine from scientific evidence to clinical practice
Ali Baran Budak, Tuğra Gençpınar, Emre Doğan, et al.
Turkish Journal of Vascular Surgery (2022) Vol. 31, Iss. 3, pp. 195-206
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top